A feasibility study evaluating the uptake, effectiveness and acceptability of routine screening of pregnant migrants for latent tuberculosis infection in antenatal care: a research protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
04 04 2022
Historique:
entrez: 5 4 2022
pubmed: 6 4 2022
medline: 7 4 2022
Statut: epublish

Résumé

Globally, tuberculosis (TB) is a leading cause of death in women of reproductive age and there is high risk of reactivation of latent tuberculosis infection (LTBI) in pregnancy. The uptake of routine screening of migrants for LTBI in the UK in primary care is low. Antenatal care is a novel setting which could improve uptake and can lend insight into the feasibility and acceptability of offering opt-out screening for LTBI. This is an observational feasibility study with a nested qualitative component. The setting will be the antenatal clinics in three hospitals in East London, UK . Inclusion criteria are pregnant migrant women aged 16-35 years attending antenatal clinics who are from countries with a TB incidence of greater than 150/100 000 including sub-Saharan Africa, and who have been in the UK for less than 5 years. Participants will be offered LTBI screening with an opt-out interferon gamma release assay blood test, and be invited to complete a questionnaire. Both participants and healthcare providers will be invited to participate in semistructured interviews or focus groups to evaluate understanding, feasibility and acceptability of routine opt-out LTBI screening. The primary analysis will focus on estimating the uptake of the screening programme along with the corresponding 95% CI. Secondary analysis will focus on estimating the test positivity. Qualitative analysis will evaluate the acceptability of offering routine opt-out LTBI screening to participants and healthcare providers. The study has received the following approvals: Health Research Authority (IRAS 247388) and National Health Service Ethics Committee (19/LO/0557). The results will be made available locally to antenatal clinics and primary care physicians, nationally to NHS England and Public Health England and internationally through conferences and journals. NCT04098341.

Identifiants

pubmed: 35379641
pii: bmjopen-2021-058734
doi: 10.1136/bmjopen-2021-058734
pmc: PMC8981348
doi:

Banques de données

ClinicalTrials.gov
['NCT04098341']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e058734

Subventions

Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Références

J Obstet Gynaecol. 2012 Oct;32(7):635-8
pubmed: 22943707
Lancet Glob Health. 2014 Jun;2(6):e323-33
pubmed: 25103301
Obstet Gynecol. 2020 Jun;135(6):1444-1453
pubmed: 32459437
Thorax. 2000 Feb;55(2):129-32
pubmed: 10639530
BMC Infect Dis. 2014 Nov 19;14:617
pubmed: 25407883
Gut. 1993;34(2 Suppl):S45-7
pubmed: 8314491
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Microbiol Spectr. 2017 Jan;5(1):
pubmed: 28155816
BJOG. 2017 Apr;124(5):727-733
pubmed: 27862893
Lancet. 2015 Jan 24;385(9965):312-3
pubmed: 25608753
Lancet Infect Dis. 2016 Nov;16(11):1269-1278
pubmed: 27522233
Clin Infect Dis. 2012 Dec;55(11):1532-49
pubmed: 22942202
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751410
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Lancet Respir Med. 2017 Nov;5(11):846-848
pubmed: 29033268
Lancet HIV. 2015 Jun;2(6):e229-35
pubmed: 26423195
Lancet. 2007 May 5;369(9572):1528-1534
pubmed: 17482983
Int J Infect Dis. 2017 Mar;56:105-110
pubmed: 27979785
BMJ. 2016 Jan 19;532:h6895
pubmed: 26786744
JAMA. 2010 Jul 21;304(3):348-9
pubmed: 20639572
Am J Respir Crit Care Med. 2012 Apr 1;185(7):779-84
pubmed: 22161161
Eur Respir J. 2018 Jan 11;51(1):
pubmed: 29326327
Health Psychol. 2009 Nov;28(6):675-81
pubmed: 19916635

Auteurs

A Rahman (A)

Blizard Institute, Queen Mary University of London, London, UK ananna.rahman1@nhs.net.

Shakila Thangaratinam (S)

Institute of Translational Medicine, Birmingham University, Birmingham, UK.

Andrew Copas (A)

Institute for Global Health, UCL, London, UK.

D Zenner (D)

Institute of Population Health Sciences, Queen Mary University of London, London, UK.

Peter J White (PJ)

MRC Centre for Global Infectious Disease Analysis and NIHR Health Protection Research Unit in Modelling and Health Economics, Imperial College, London, UK.
Modelling and Economics Unit, Public Health England, London, UK.

Chris Griffiths (C)

Institute of Population Health Sciences, Queen Mary University of London, London, UK.

Ibrahim Abubakar (I)

Tuberculosis Section, Centre for Infections, Health Protection Agency, London, UK.

Christine McCourt (C)

Department of Midwifery and Child Health, City University London, London, UK.

Heinke Kunst (H)

Department of Respiratory Medicine, Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH